Evaluating the potential of cross-species neutralization of anti-PfCyRPA and anti-PfRIPR monoclonal antibodies

PfCyRPA and PfRIPR are promising next-generation blood-stage vaccine candidates that play a crucial role in erythrocyte invasion of Plasmodium species. CyRPA and RIPR orthologs are present in all human-infecting Plasmodium species, suggesting the potential for a cross-species vaccine. Using Growth Inhibition Assays (GIA), this study investigates seven anti-PfCyRPA and three anti-PfRIPR monoclonal antibodies targeting P. falciparum for their inhibitory activity against P. knowlesi, a non-falciparum species that contributes to a significant burden of disease in South Asia, shares some biological features with Plasmodium vivax,  and has a robust in vitro culture system. Despite their efficacy against P. falciparum and partially conserved epitopes, these antibodies exhibited minimal inhibition of P. knowlesi. Understanding the antigenic diversity and immune mechanisms across Plasmodium species is critical for advancing pan-species vaccine strategies.
,
Monoclonal antibody production

Seven previously characterized anti-PfCyRPA mAbs (Cy.002, Cy.003, Cy.004, Cy.007, Cy.009, 8A7, and 5B12) and three previously characterized anti-PfRIPR mAbs (1C4, 5G6, 1G12) were produced as previously described). Briefly, Cy.003, Cy.004, Cy.007, and Cy.009 mAbs were produced by Icosagen using HybriFree Technology. Spleen cells from immunized chickens were panned against antigen-coated immune modules. RNA that was extracted from bound cells were used to synthesize cDNA and amplify variable light and heavy chains. Amplified variable light and heavy chains were purified and cloned into human immunoglobulin G1 expression vectors. Cy.002, 8A7, and 5B12 were produced from immunized mice, while 1C4, 5G6, and 1G12 were produced from immunized rabbits. Spleen cells from immunized mice or rabbits were fused with myeloma cells and positive antibody-producing hybridoma cell lines were identified using ELISA. For 8A7, 5B12, 1C4, 5G6, and 1G12, positive hybridom..., # Evaluating the potential of cross-species neutralization of anti-PfCyRPA and anti-PfRIPR monoclonal antibodies

Dataset DOI: [10.5061/dryad.0cfxpnwfw](https://doi.org/10.5061/dryad.0cfxpnwfw)

## Description of the data and file structure

The data contains growth inhibition assay data for all antibodies used in the study. Percent inhibition is calculated as 100-[(Parasitemia of test mAb)/(Parasitemia of Naïve IgG control)x100]). The data is organized in a single tab, with all analysis types contained in it and a tab for the codebook. There are two types of analyses for which data is included: 1) PkYH1 (*P. knowlesi*) GIA, which gives percent GIA for the anti-CyRPA monoclonal antibodies (Cy.002, Cy.003, Cy.004, Cy.007, Cy.009, 8A7, and 5B12), anti-RIPR monoclonal antibodies (1C4, 5G6, 1G12 ), combinations of anti-CyRPA monoclonal antibodies (Cy.003_Cy.009, Cy.004_Cy.007, Cy.007_Cy.009 ), and controls including anti-Duffy, anti-Basigin, and Naïve IgG antibodies; 2) Pf3D7 (*P. falcipar...,